Clinical application of biochemical markers of bone turnover

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 50, Issue 4, 2006, Pages 603-620

  Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Fracture; Markers; Osteoporosis; Remodelling; Treatment

Indexed keywords

EID: 33751227483     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302006000400006     Document Type: Review

References (151)

1. Seibel MJ. Bone metabolism. In: Offermanns S, Rosenthal W (eds.). Encyclopaedic Reference of Molecular Pharmacology. Nova York: Springer Heidelberg, 2003. pp. 457-65.
2. Dunstan CR, Seibel MJ. Bone and mineral metabolism. In: Encyclopedia of Medicinal Chemistry. In press.
3. Seibel MJ. Biochemical markers of bone turnover. Part I: Biochemistry and Variability. Clin Biochem Rev 2005;26:97-122.
4. Beardsworth LJ, Eyre DR, Dickson IR. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res 1990;5:671.
5. Midtby M, Magnus J, Joakimsen R. The Tromso Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int 2001;12:835-43.
6. Meier C, Liu PY, Handelsman DJ, Seibel MJ. Endocrine regulation of bone turnover in men. Clin Endocrinol 2005;63:603-16.
7. Meier C, Liu PY, Seibel MJ, Handelsman DJ. Sex steroids and skeletal health in men. In: Lane NE, Sambrook PN (eds.). Osteoporosis and the Osteoporosis of Rheumatic Diseases. Nova York: Mosby, 2006.
8. Epstein S, McClintock R, Bryce G, Poser J, Johnston C, Hui S. Differences in serum bone gla protein with age and sex. Lancet 2006;11:307-10.
9. Hassager C, Risteli J, Risteli L, Christiansen C. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporos Int 1994;4:349-52.
10. Koshla S, Atkinson E, Melton LJ, Riggs BL. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population based study. J Clin Endocrinol Metab 1997;82:1522-7.
11. Kushida K, Takahashi M, Kawana K, Inoue T. Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 1995;80:2447-50.
12. Seibel MJ, Cosman F, Shen V, Ratcliffe A, Lindsay R. Urinary hydroxy-pyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Min Res 1993;8:881-9.
13. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, et al. Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994;9:1433-40.
14. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 1991;72:367-73.
15. Cleghorn DB, O'Loughlin PD, Schroeder BJ, Nordin BE. An open, crossover trial of calcium-fortified milk in prevention of early postmenopausal bone loss. Med J Aust 2001;175(5):242-5.
16. Rosen C, Chesnut CH III, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
17. Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, et al. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int 2004;74:415-23.
18. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 2004;19:1221-30.
19. Meunier PJ, Jenvrin C, Munoz F, de la Gueronniere V, Garnero P, Menz M. Consumption of a high calcium mineral water lowers biochemical indices of bone remodeling in postmenopausal women with low calcium intake. Osteoporosis Int 2005;16:1203-9.
20. Chesnut CH, Bell N, Clark G, Drinkwater BL, English SC, Johnson CC Jr, et al. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
21. Harris ST, Eriksen EF, Davidson M, Ettinger MP, Moffett Jr AH, Baylink DJ, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001;86(5):1890-7.
22. Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kroger H, et al. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: A prospective, controlled, randomized study. J Clin Endocrinol Metabolism 1997;82:2476-82.
23. Prestwood K, Pilbeam C, Burleson J, Woodiel FN, Delmas PD, Deftos LJ, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-71.
24. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005;90:2762-7.
25. Seifert-Klauss V, Mueller JE, Luppa P, Probst R, Wilker J, Hoss C, et al. Bone metabolism during the perimenopausal transition: a prospective study. Maturitas 2002;41:23-33.
26. McKane W, Khosla S, Risteli J, Robins S, Muhs J, Riggs B. Role of estrogen deficiency in pathogenesis of secondary hyperparathyroidism and increased bone resorption in elderly women. Proc Assoc Am Physicians 1997;109:174-80.
27. Wasnich RD, Bagger Y, Hosking D, McClung M, Wu M, Mantz AM, et al; Early Postmenopausal Intervention Cohort Study Group. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11:622-30.
28. Akesson K, Ljunghall S, Gardsell P, Sernbo I, Obrant KJ. Serum osteocalcin and fracture susceptibility in elderly women. Calcif Tissue Int 1993;53:86-90.
29. Akesson K, Vergnaud P, Gineyts E, Delmas PD, Obrant KJ. Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 1993;53:162-9.
30. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 1996 59:328-33.
31. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Min Res 1996;11:337-49.
32. Chen JS, Cameron ID, Cumming RG, March LM, Sambrook PN, Simpson JM, et al. Effect of age-related chronic immobility on markers of bone turnover. J Bone Miner Res 2006;21:324-31.
33. Sambrook PN, Chen JS, March L, Cameron ID, Cumming RG, Lord S, et al. High bone turnover is an independent predictor of mortality in the frail elderly. J Bone Miner Res 2006;21:549-55.
34. Mezquita-Raya P, Munoz-Torres M, Luna JD, Luna V, Lopez-Rodriguez F, Torres-Vela E, et al. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res 2001;16(8):1408-15.
35. Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population. J Clin Endocrinol Metab 2004;89:1572-6.
36. Sambrook PN, Chen JS, March LM, Cameron ID, Cumming RG, Lord SR, et al. Serum parathyroid hormone is associated with increased mortality independent of 25-hydroxy vitamin D status, bone mass, and renal function in the frail and very old: A cohort study. J Clin Endocrinol Metab 2004;89:5477-81.
37. Zochling J, Chen JS, Seibel M, Schwarz J, Cameron ID, Cumming RG, et al. Calcium metabolism in the frail elderly. Clin Rheumatol 2005;24:576-82.
38. Charles P, Hasling C, Risteli L, Risteli J, Mosekilde L, Eriksen E. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level. Calc Tissue Int 1992;51:406-11.
39. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79(6):1693-700.
40. McLarren AM, Hordon LD, Bird HA, Robins SP. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992;51:648-51.
41. Meier C, Meinhardt U, Greenfield JR, Nguyen TV, Dunstan CR, Seibel MJ. Serum cathepsin K levels reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clin Lab 2006;52:1-10.
42. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-5.
43. Akesson K, Ljunghall S, Jonsson B, Sernbo I, Johnell O, Gardsell P, et al. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: A retrospective and prospective population-based study in women. J Bone Miner Res 1995;10:1823-9.
44. Akesson K, Vergnaud P, Delmas PD, Obrant KJ. Serum osteocalcin increases during fracture healing in elderly women with hip fracture. Bone 1995;6:427-30.
45. Ensrud KE, Palermo L, Black DM, Cauley J, Jergas M, Orwoll ES, et al. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures. J Bone Min Res 1995;10:1778-87.
46. Meier C, Liu PY, Ly LP, de Winter-Modzelewski J, Jimenez M, Handelsman DJ, et al. Recombinant human chorionic gonadotropin, but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age related androgen deficiency. J Clin Endocrinol Metab 2004;89:3033-41.
47. Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, et al. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:5212-6.
48. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464-70.
49. Jamal SA, Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res 2004;19:1512-7.
50. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen L, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004;19:737-44.
51. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 2003;88:5650-5.
52. Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub JJ, Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. Osteoporos Int 2004;15:209-16.
53. Mallmin H, Ljunghall S, Larsson K. Biochemical markers of bone metabolism in patients with fracture of the distal forearm. Clin Orthop 1993;295:259-63.
54. Obrant KJ, Merle B, Bejui J, Delmas PD. Serum bone-gla protein after fracture. Clin Orthop 1990;258:300-3.
55. Hansen M. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women. Osteoporos Int 1994;4:123-8.
56. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 1987;8:279-84.
57. Stepan JJ, Presl J, Broulik P, Pacovsky V. Serum osteocalcin levels and bone alkaline phosphatase isoenzyme after oophorectomy and in primary hyperparathyroidism. J Clin Endocrinol Metab 1987;64:1079-82.
58. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 1995;80:3304-10.
59. Melton L, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone fractures to bone density and fractures. J Bone Mineral Res 1997;12:1083-91.
60. Christiansen C, Riis BJ, Rodboro P. Prediction of rapid bone loss in postmenopausal women. Lancet 1987;1:1105-8.
61. Christiansen C, Riis BJ, Rodbro P. Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos Int 1990;1:35-40.
62. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 1996;58:236-43.
63. Mole PA, Walkinshaw MH, Robins SP, Paterson CR. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause? Eur J Clin Invest 1992;22:767-71.
64. Reeve J, Pearson J, Mitchell A, Green J, Nicholls A, Justice J, et al. Evolution of spinal bone loss and biochemical markers of bone remodeling after menopause in normal women. Calcf Tissue Int 1995;57:105-10.
65. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297-302.
66. Keen RW, Nguyen T, Sobnack R, Perry LA, Thompson PW, Spector TD. Can biochemical markers predict bone loss at the hip and spine? A 4-year prospective study of 141 early postmenopausal women. Osteoporos Int 1996;6:399-406.
67. Blumsohn A, Eastell R. Prediction of bone loss in postmenopausal women. Eur J Clin Invest 1992;22:764-6.
68. Vestergaard P, Hermann AP, Gram J, Jensen LB, Eiken P, Abrahamsen B, et al. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas 2001;40(3):211-20.
69. Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996;18:197-201.
70. Van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JP, et al. Case control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 1996;312:482-3.
71. Weel A, Seibel MJ, Pols HAP, et al. Bone resorption and risk of non-vertebral fractures - a populations-based study: The Rotterdam study. J Bone Miner Res 2002;17:S356.
72. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fractures in elderly women. The EPIDOS study. J Bone Miner Res 1996;11:1531-8.
73. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K, Delmas PD. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women. The EPIDOS study. J Clin Endocrinol Metab 1997;82:719-24.
74. Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994;9:1591-5.
75. Szulc P, Chapuy MC, Meunier P, Delmas P. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993;91:1769-74.
76. Szulc P, Chapuy MC, Meunier P, Delmas P. Serum under-carboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996;18:487-8.
77. Price PA, Kaneda Y. Vitamin D counteracts the effect of warfarin in liver but not in bone. Thromb Res 1987;46:121-31.
78. Hodges SJ, Pilkington MJ, Stamp TC, Catterall A, Shearer MJ, Bitensky L, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone 1991;12:387-9.
79. Knapen MH, Manulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin and urinary calcium excretion. Ann Int Med 1989;111:1001-5.
80. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA. Bone resorption and osteoporotic fractures in elderly men: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2005;20:579-87.
81. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, et al. Bone turnover in postmenopausal osteoporosis. J Clin Invest 1988;82:1268-74.
82. Nielsen NM, Von der Recke P, Hansen MA, Overgaard K, Christensen C. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif Tissue Int 1994;55:8-11.
83. Overgaard K, Hansen MA, Nielsen VH, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis. Effects of withdrawal and treatment. Am J Med 1990;89:1-6.
84. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 1999;65(5):359-64.
85. Stevenson JC, Hillard TC, Lees B, Whitcroft SI, Ellerington MC, Whitehead MI. Postmenopausal bone loss: does HRT always work? Int J Fertil Stud 1993;38(suppl.2):88-91.
86. Seibel MJ, Naganathan V, Barton I, Grauer A. Vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate: the role of pre-treatment bone turnover. J Bone Mineral Res 2004;19:323-9.
87. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al.; for the Fracture Intervention Research Group. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006;21(2):292-9.
88. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al.; for the AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31.
89. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20(10):1804-12.
90. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61.
91. Tahtela R, Seppanen J, Laitinen K, Katajamaki A, Risteli J, Valimaki MJ. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporosis Int 2005;16:1109-16.
92. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al.; for the Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8.
93. Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-9.
94. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004;19:394-401.
95. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 2004;34:344-51.
96. Tanko LB, Mouritzen U, Lehmann H, Warming L, Moelgaard A, Christgau S, et al. Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. Bone 2003;32:687-93.
97. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
98. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al.; for the PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
99. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566-75.
100. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al.; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65.
101. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-53.
102. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70.
103. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
104. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
105. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
106. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
107. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
108. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10.
109. Li Z, Meredith MP. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 2003;13:777-92.
110. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
111. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas P, Christiansen C. Six and twelve-month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12:922-30.
112. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas P. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
113. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48(3):271-87.
114. Marwick C. Hormone combination treats women's bone loss. JAMA 2004;272:1487.
115. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre. Maturitas 1994;20:91-9.
116. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226-9.
117. Kotzan JA, Martin BC, Wade WE. Persistence with estrogen therapy in a postmenopausal Medicaid population. Pharmacotherapy 1999;19:363-9.
118. Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001;8:328-32.
119. Bjorn I, Backsrom T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86.
120. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003;5:859-62.
121. Chapurlat RD, Cummings SR. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporos Int 2002;13:738-44.
122. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23.
123. Delmas PD, Vrijens B, Roux C, et al. A reinforcement message based on bone turnover marker response influences long-term persistence with risedronate in osteoporosis: The IMPACT Study. J Bone Miner Res 2003;18:S374.
124. Di Munno O, Mazzantini M, Braga V, Adami S. The DOMINO Project: To improve the compliance of osteoporotic patients with periodic feedback of urinary CTX values. J Bone Miner Res 2002;17:S374.
125. Hashimoto K, Nozaki M, Yokoyama M, Sano M, Nakano H. Urinary excretion of pyridinium crosslinks of collagen in oophorectomized women as markers for bone resorption. Maturitas 1994;18:135-42.
126. Seibel MJ, Gartenberg F, Ratcliffe A, Robins SP, Silberberg J, Bilezikian JP. Urinary hydroxy-pyridinium crosslinks of collagen as specific indices of bone resorption in primary hyperparathyroidism. J Clin Endocrinol Metabol 1992;74:481-6.
127. Seibel MJ. Bone turnover in primary hyperparathyroidism. In: Bilezikian JP, Marcus R (eds). The Parathyroids. San Diego: Academic Press, 2001. pp. 399-410.
128. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
129. Woitge HW, Müller M, Ziegler R, Bärtsch W, Seibel MJ. Effect of aerobic and anaerobic physical training on markers of bone metabolism. J Bone Miner Res 1998;13:1796-805.
130. Yamauchi M, Young DR, Chandler GS, Mechanic GL. Cross-linking and new bone collagen synthesis in immobilized and recovering primate osteoporosis. Bone 1988;9:415-21.
131. Nyquist F, Ljunghall S, Berglund M, Obrant K. Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. Bone 1996;19:51-4.
132. Szulc P, Garnero P, Claustrat B, Marchand F, Duboeuf F, Delmas PD. Increased bone resorption in moderate smokers with low body weight: the Minos study. J Clin Endocrinol Metab 2002;87(2):666-74.
133. Meunier P. Prevention of hip fractures by correcting calcium and vitamin D insufficiencies in elderly people. Scand J Rheumatol 1996;103:S75-78.
134. Cortet B, Cortet C, Blanckaert F, d'Herbomez M, Marchandise X, Wemeau J-L, et al. Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporos Int 2001;12:117-23.
135. Schoon E, Geerling B, Van Dooren I, Schurgers LJ, Vermeer C, Brummer RJ, et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Alim Pharmacol Ther 2001;15:783-92.
136. Zipfel S, Seibel MJ, Löwe B, Beumont PJ, Kasperk C, Herzog C. Osteoporosis in eating disorders: a follow-up study of patients with anorexia and bulimia nervosa. J Clin Endocrinol Metab 2001;86:5227-33.
137. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 1994;78:955-9.
138. Bijlsma JW, Lems WF, Gerrits MI, Jacobs JW, vanVugt RM, vanRijn HJ. Effect of high-dose corticosteroid pulse therapy on (markers of) bone formation and resorption in rheumatoid arthritis. Calcif Tissue Int 1995;56:500-6.
139. King CS, Weir E, Gundberg C, Fox J, Insogna K. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996;59:184-91.
140. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med 1995;151:333-6.
141. Anderson FH, Francis RM, Peaston RT, Wastell HJ. Androgen supplementation in eugonadal men: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997;12:472-8.
142. Seibel MJ, Woitge HW, Parviz M, Sillem M, Kiesel L, Pfeilschifter J, et al. Medrogestone prevents accelerated bone turnover in GnRH analogue treated endometriosis. Clin Lab 1996;42:1075-8.
143. Philip WJU, Martin JC, Richardson JM, Reid DM, Webster J, Douglas AS. Decreased axial and peripheral bone density in patients taking long-term warfarin. QJ Med 1995;88:635-40.
144. Valk NK, Erdtsieck RJ, Algra D, Lamberts SW, Pols HAP. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: The effects on renal phosphate handling, bone turnover and bone mineral mass. Clin Endocrinol 1995;43:317-24.
145. Woitge H, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, et al. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 2001;84:344-51.
146. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
147. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nature CP Oncol 2005;2:504-17.
148. Lipton A, Demers L, Curley E, Chinchilli V, Gaydos L, Hortobagyi G, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6.
149. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-36.
150. Luftner D, Richter A, Geppert R, Wernecke KD, Possinger K. Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 2003;23:1017-26.
151. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997;8:1243-50.